Maverick Capital, M28 Capital, and Population Health Partners led a $100m Series F Round in Fractyl, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic. "We’re immensely proud of the leadership role Fractyl has established in creating innovative treatments to address the root cause of metabolic disease, with an initial focus on type 2 diabetes. The closing of this Series F financing, the significant experience of our new board members and our company’s renaming as Fractyl Health reflect the momentum we have built and the vast potential that lies ahead for our approach," Harith Rajagopalan, Fractyl CEO.